Assenagon Asset Management S.A. Exelixis, Inc. Transaction History

Assenagon Asset Management S.A.

$65.1 Billion
Q3 2025

A detailed history of Assenagon Asset Management S.A. transactions in Exelixis, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 708,214 shares of EXEL stock, worth $27.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

708,214

Previous 623,927 13.51%

Holding current value

$27.6 Million

Previous $27.5 Million 6.35%

% of portfolio

0.04%

Previous 0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 07, 2025	BUY	$36.22 - $46.25 $3.05 Million - $3.9 Million	84,287 Added 13.51%	708,214 $29.2 Million
Q2 2025 Jul 11, 2025	SELL	$34.13 - $46.26 $3.71 Million - $5.02 Million	-108,572 Reduced 14.82%	623,927 $27.5 Million
Q1 2025 Apr 15, 2025	BUY	$32.38 - $39.16 $16.5 Million - $20 Million	510,586 Added 230.08%	732,499 $27 Million
Q4 2024 Jan 14, 2025	SELL	$25.39 - $36.46 $22.6 Million - $32.4 Million	-889,445 Reduced 80.03%	221,913 $7.39 Million
Q3 2024 Oct 23, 2024	SELL	$21.96 - $27.6 $12.9 Million - $16.3 Million	-588,870 Reduced 34.63%	1,111,358 $28.8 Million
Q2 2024 Jul 18, 2024	SELL	$20.34 - $23.73 $1.35 Million - $1.58 Million	-66,374 Reduced 3.76%	1,700,228 $38.2 Million
Q1 2024 Apr 24, 2024	SELL	$20.17 - $23.93 $3.69 Million - $4.38 Million	-182,841 Reduced 9.38%	1,766,602 $41.9 Million
Q4 2023 Jan 17, 2024	SELL	$19.25 - $24.13 $7.1 Million - $8.9 Million	-368,961 Reduced 15.91%	1,949,443 $46.8 Million
Q3 2023 Nov 06, 2023	SELL	$19.04 - $22.74 $65 Million - $77.6 Million	-3,414,517 Reduced 59.56%	2,318,404 $50.7 Million
Q2 2023 Jul 25, 2023	BUY	$18.17 - $20.48 $42.1 Million - $47.4 Million	2,315,458 Added 67.75%	5,732,921 $110 Million
Q1 2023 Apr 18, 2023	BUY	$16.3 - $19.41 $22.5 Million - $26.8 Million	1,381,656 Added 67.87%	3,417,463 $66.3 Million
Q4 2022 Jan 12, 2023	SELL	$14.96 - $17.39 $210,217 - $244,364	-14,052 Reduced 0.69%	2,035,807 $32.7 Million
Q3 2022 Oct 27, 2022	BUY	$15.68 - $22.27 $2.78 Million - $3.95 Million	177,189 Added 9.46%	2,049,859 $32.1 Million
Q2 2022 Jul 27, 2022	BUY	$17.44 - $23.16 $29.5 Million - $39.1 Million	1,689,126 Added 920.28%	1,872,670 $39 Million
Q1 2022 Apr 25, 2022	SELL	$17.03 - $22.67 $2.12 Million - $2.82 Million	-124,564 Reduced 40.43%	183,544 $4.16 Million
Q4 2021 Feb 01, 2022	BUY	$15.84 - $21.88 $4.63 Million - $6.4 Million	292,316 Added 1851.04%	308,108 $5.63 Million
Q3 2021 Oct 19, 2021	SELL	$16.3 - $21.14 $5.48 Million - $7.1 Million	-336,000 Reduced 95.51%	15,792 $334,000
Q1 2021 Apr 26, 2021	SELL	$20.53 - $25.22 $38.1 Million - $46.8 Million	-1,856,516 Reduced 84.07%	351,792 $7.95 Million
Q4 2020 Feb 01, 2021	BUY	$18.39 - $24.8 $40.6 Million - $54.8 Million	2,208,308 New	2,208,308 $44.3 Million
Q3 2020 Oct 07, 2020	SELL	$20.67 - $26.94 $3.41 Million - $4.45 Million	-165,173 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$16.46 - $27.42 $2.72 Million - $4.53 Million	165,173 New	165,173 $3.92 Million
Q1 2020 Apr 17, 2020	SELL	$14.46 - $21.8 $929,300 - $1.4 Million	-64,267 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$15.15 - $18.89 $973,645 - $1.21 Million	64,267 New	64,267 $1.13 Million
Q3 2019 Oct 16, 2019	SELL	$17.68 - $22.65 $1.91 Million - $2.45 Million	-108,134 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$18.93 - $24.75 $2.05 Million - $2.68 Million	108,134 New	108,134 $2.31 Million
Q1 2019 Apr 26, 2019	SELL	$19.6 - $24.76 $7.61 Million - $9.62 Million	-388,443 Closed	0 $0
Q4 2018 Jan 23, 2019	BUY	$13.65 - $21.8 $5.3 Million - $8.47 Million	388,443 New	388,443 $7.64 Million

Others Institutions Holding EXEL

# of Institutions

696

Shares Held

259M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Exelixis, Inc. Transaction History